Free Trial

Silverback Therapeutics (SBTX) 10K Form and Latest SEC Filings 2026

Silverback Therapeutics logo
$8.56 +0.30 (+3.63%)
As of 05/1/2026

Latest Silverback Therapeutics SEC Filings & Recent Activity

Silverback Therapeutics (NASDAQ:SBTX) has submitted 344+ documents to the U.S. Securities and Exchange Commission (SEC) since 2018. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Silverback Therapeutics's financial statements. The most recent filing was a Form ARS submitted on April 29, 2026.

8-K
Silverback Therapeutics Files Current Report on Mar. 9, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-K
Silverback Therapeutics Files Annual Report on Mar. 9, 2026

The 10-K contains Silverback Therapeutics's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Silverback Therapeutics SEC Filing History

Browse Silverback Therapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
04/29/2026 3:04 PM
Silverback Therapeutics (1671858) Filer
Form DEFA14A
04/29/2026 3:05 PM
Silverback Therapeutics (1671858) Filer
Form ARS
03/31/2026 5:43 PM
Silverback Therapeutics (1671858) Subject
MILLENNIUM MANAGEMENT LLC (1273087) Filed by
Form SCHEDULE 13G/A
03/24/2026 3:18 PM
Silverback Therapeutics (1671858) Subject
MILLENNIUM MANAGEMENT LLC (1273087) Filed by
Form SCHEDULE 13G
03/09/2026 5:01 AM
Silverback Therapeutics (1671858) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/09/2026 5:07 AM
Silverback Therapeutics (1671858) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
01/05/2026 3:20 PM
Silverback Therapeutics (1671858) Issuer
Tanimoto Sarina (1951291) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2026 3:19 PM
Silverback Therapeutics (1671858) Issuer
Lowenthal Richard E (1378550) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/14/2025 5:41 PM
Silverback Therapeutics (1671858) Issuer
Shah Pratik (1580787) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/14/2025 5:42 PM
Silverback Therapeutics (1671858) Issuer
Chakma Justin (1951238) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/14/2025 5:43 PM
Silverback Therapeutics (1671858) Issuer
Dorsey Brian (1380762) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/12/2025 4:26 PM
Silverback Therapeutics (1671858) Subject
Chakma Justin (1951238) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/12/2025 9:56 AM
Silverback Therapeutics (1671858) Subject
Chakma Justin (1951238) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/12/2025 10:09 AM
Silverback Therapeutics (1671858) Subject
Chakma Justin (1951238) Reporting
Form 144/A
11/10/2025 5:02 AM
Silverback Therapeutics (1671858) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/10/2025 5:04 AM
Silverback Therapeutics (1671858) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/01/2025 8:19 PM
Silverback Therapeutics (1671858) Subject
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Form SCHEDULE 13D/A
09/29/2025 3:15 PM
Silverback Therapeutics (1671858) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/27/2025 8:45 PM
Silverback Therapeutics (1671858) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/22/2025 3:30 PM
Silverback Therapeutics (1671858) Issuer
Scott Kathleen D. (1794284) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/22/2025 3:30 PM
Silverback Therapeutics (1671858) Issuer
Lowenthal Richard E (1378550) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/21/2025 4:36 PM
Silverback Therapeutics (1671858) Issuer
Tanimoto Sarina (1951291) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/21/2025 3:18 PM
Silverback Therapeutics (1671858) Subject
Scott Kathleen D. (1794284) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/21/2025 10:20 AM
Silverback Therapeutics (1671858) Subject
Lowenthal Richard E (1378550) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/19/2025 9:22 AM
Silverback Therapeutics (1671858) Subject
Tanimoto Sarina (1951291) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/13/2025 6:02 AM
Silverback Therapeutics (1671858) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/13/2025 6:03 AM
Silverback Therapeutics (1671858) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/01/2025 5:06 PM
Silverback Therapeutics (1671858) Subject
Flynn James E (1352546) Filed by
Form SCHEDULE 13D/A
07/22/2025 6:38 PM
Silverback Therapeutics (1671858) Subject
Flynn James E (1352546) Filed by
Form SCHEDULE 13D/A
07/02/2025 7:24 AM
Silverback Therapeutics (1671858) Subject
Flynn James E (1352546) Filed by
Form SCHEDULE 13D/A
07/01/2025 3:42 PM
Silverback Therapeutics (1671858) Issuer
DEERFIELD MANAGEMENT COMPANY, L.P. (0) SERIES C
Deerfield Mgmt III, L.P. (1610540) Reporting
Deerfield Mgmt IV, L.P. (1713467) Reporting
Deerfield Private Design Fund III, L.P. (1603333) Reporting
Deerfield Private Design Fund IV, L.P. (1680307) Reporting
Flynn James E (1352546) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/27/2025 4:21 PM
Silverback Therapeutics (1671858) Issuer
Kolchinsky Peter (1384859) Reporting
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
RA Capital Nexus Fund II, L.P. (1825376) Reporting
Shah Rajeev M. (1619841) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/27/2025 3:43 PM
Silverback Therapeutics (1671858) Issuer
Dadoo Rajeev (1951685) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/27/2025 3:30 PM
Silverback Therapeutics (1671858) Issuer
Shawver Laura (1551891) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/27/2025 3:30 PM
Silverback Therapeutics (1671858) Issuer
SCHNEIDER PHILLIP M (1230051) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/27/2025 3:30 PM
Silverback Therapeutics (1671858) Issuer
SAUNDERS BRENT L (1268854) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/27/2025 3:30 PM
Silverback Therapeutics (1671858) Issuer
Thompson Peter A. (1357522) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/27/2025 3:30 PM
Silverback Therapeutics (1671858) Issuer
Islam Saqib (1575408) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/27/2025 3:30 PM
Silverback Therapeutics (1671858) Issuer
Kelly Michael (1952533) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/27/2025 3:30 PM
Silverback Therapeutics (1671858) Issuer
Shah Pratik (1580787) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/26/2025 3:15 PM
Silverback Therapeutics (1671858) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/20/2025 5:38 PM
Silverback Therapeutics (1671858) Issuer
Karas Eric (1951287) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/18/2025 3:51 PM
Silverback Therapeutics (1671858) Subject
Karas Eric (1951287) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/20/2025 4:24 PM
Silverback Therapeutics (1671858) Subject
Scott Kathleen D. (1794284) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/20/2025 3:48 PM
Silverback Therapeutics (1671858) Subject
SAUNDERS BRENT L (1268854) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/20/2025 3:50 PM
Silverback Therapeutics (1671858) Subject
Fitzpatrick Alexander A (1398595) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/14/2025 6:01 AM
Silverback Therapeutics (1671858) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/14/2025 6:03 AM
Silverback Therapeutics (1671858) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

Silverback Therapeutics SEC Filings - Frequently Asked Questions

Silverback Therapeutics (SBTX) has submitted 344+ filings to the SEC since 2018. You can browse the complete history or filter by form type using the tools above.

Silverback Therapeutics's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Silverback Therapeutics's financial statements page.

The most recent filing was a Form ARS submitted on April 29, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:SBTX) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners